Catalysts

A catalyst is an event that can change what a company is worth — a trial result, an approval decision, a merger, a big contract. The Catalysts board collects the upcoming ones, reads the company’s own filings and releases, and tells you what’s pending, when, and how much it could matter.

Reading a row

• Catalyst — the event in a plain sentence, with tags for its type and outlook (▲ Positive, ▼ Risk, ● Neutral). Pending means it hasn’t happened yet.
• Impact — High, Medium or Low: how big and how concrete the event is for a company of that size. It says nothing about timing or which way the stock will move.
• Timeline — when the event is expected. A plain period (“Q3 2026”) is the company’s own word; a “~” means it’s our estimate from the filing’s text. Past due means the stated date passed with no news; No date means the company never gave one; Ongoing is work in progress, like a trial still enrolling.
• Delayed ×N — the company has pushed this date back before — treat it with caution.

The detail panel

Click a row to open it: the company in a sentence, the main catalyst with its source, other events still in play, and the history of what already happened. It also shows the company’s dilution picture and cash runway — see the risk gauges guide for how to read them.

Biotech

The Biotech view lists every pending drug and device event as its own row — one company can appear several times, once per program. The stage rail shows how far the program has come (from preclinical to approval) and its next step: planned, enrolling, data pending, under review, or gated (waiting on a partner or money). Where there’s a registered trial, the public registry’s date sits under the company’s as a second opinion, with a link to the study.

Filters and saved views

More filters narrows by market cap, float, timeline, industry, keyword or — on Biotech — type, stage and next step. Save filters keeps a set under Catalysts in the sidebar; two starter views (small and larger companies) are there from day one.